Interviews

DirectorsTalk Interviews brings investors closer to the people behind listed companies, markets and sectors. We feature interviews with CEOs from UK, US and Canadian companies, alongside fund managers, analysts and sector specialists, giving audiences direct insight into strategy, performance, opportunities and risks. Each interview is designed to help investors understand the businesses shaping the market and make more informed decisions.

CentralNic Group undervalued with multiple catalysts for share price momentum (Analyst Interview)

CentralNic Group (LON:CNIC) is the topic of conversation when Zeus Capital Analyst Bob Liao joins DirectorsTalk Interviews. Bob explains whats the driving strong trading, gives us some details around the..

Cizzle Biotechnology AZD 1656 deal means near term revenue streams (Interview)

Cizzle Biotechnology Holdings plc (LON:CIZ) Executive Chairman Allan Syms joins DirectorsTalk Interviews to discuss an agreement with Conduit Pharmaceuticals and St George Street Capital to acquire a 5% economic interest..

Diverse Income Trust Gervais Williams talks macro economic conditions and investment strategies (Interview)

The Diverse Income Trust (LON:DIVI) Head of Equities Gervais Williams joins DirectorsTalk Interviews to discuss some of the macro economic conditions facing companies; the sort of investment strategy investors should..

Dekel Agri-Vision ‘Excellent results can still be beaten’ says Lincoln Moore (Interview)

Dekel Agri-Vision plc (LON:DKL) Executive Director Lincoln Moore joins DirectorsTalk Interviews to discuss a January production update and timing of the ramp-up of production for the large-scale cashew processing plant...

Vector Capital ahead of market expectations (Interview)

Vector Capital plc (LON:VCAP) CEO Agam Jain joins DirectorsTalk Interviews to discuss a trading update for the year ended 31 December 2021 and tell us more about the business. Agam..

Goodbody Health Phytovista Laboratories extends its ISO 17025 UKAS accreditation (Interview)

Goodbody Health Group (CSE: GDBY / AQSE: GDBY / FRA: 484 / OTC: SCNNF) subsidiary Phytovista Laboratories Chief Scientific Officer Nick Clarkson joins DirectorsTalk Interviews to discuss an extension to..

itim Group improving the financial performances of store-based retailers (Interview)

itim Group plc (LON:ITIM) Founder and CEO Ali Athar joins DirectorsTalk Interviews to tell us more about the company. Ali explains what the company does, who its typical customers are,..

Xpediator stock value looks very attractive (Analyst Interview)

Xpediator Plc (LON:XPD) is the topic of conversation when Robin Byde, Research Analyst at Zeus Capital joins DirectorsTalk Interviews. Robin reminds us what the company does, what the company announced..

Cadence Minerals excited as first phase of Amapa Iron Ore Project completes (Interview)

Cadence Minerals plc (LON:KNDC) CEO Kiran Morzaria joins DirectorsTalk Interviews to discuss its acquisition of 20% of the Amapa Iron Ore Project. Kiran explains what the acquisition entailed, its estimated..

Strix Group deliver a good performance and now look undervalued (Analyst Interview)

Strix Group plc (LON:KETL) is the topic of conversation when Andy Hanson Research Director at Zeus Capital joins DirectorsTalk Interviews. Andy shares his thoughts on the company performance from the..

Cizzle Biotechnology to take early lung cancer test to £3b China market (Interview)

Cizzle Biotechnology Holdings plc (LON:CIZ) Executive Chairman Allan Syms joins DirectorsTalk Interviews to discuss a full commercial development and royalty agreement to develop and market Cizzle Biotechnologies early lung cancer..

Open Orphan world’s first COVID-19 characterisation study (Interview)

Open Orphan plc (LON:ORPH) Executive Chairman Cathal Friel joins DirectorsTalk Interviews to discuss results from the world’s first COVID-19 characterisation study. Cathal explains what these results mean for Open Orphan,..

Tirupati Graphite ramping up to become major graphite producer (Interview)

Tirupati Graphite PLC (LON:TGR) Executive Chairman & Managing Director Shishir Poddar joins DirectorsTalk Interviews to keep us up to date with progress being made at its Graphite Mines. Shishir shares..

Quadrise Fuels bioMSAR™ Aquafuels testing results endorsement of potential (Interview)

Quadrise Fuels International plc (LON:QFI) CEO Jason Miles joins DirectorsTalk Interviews to discuss the results of the latest bioM-SAR™ testing at Aquafuel Research and also the appointment of Andy Morrison..

Fintel digitisation of SaaS & subscription business improves earnings quality (Analyst Interview)

Fintel plc (LON:FNTL) is the topic of conversation when Robin Savage, Research Analyst at Zeus Capital joins DirectorsTalk Interviews. Robin talks us through the key points in the company pre-close..

Staffline Group positive momentum to continue into FY22 (Analyst Interview)

Staffline Group plc (LON:STAF) is the topic of conversation when Mike Allen, Head of Research at Zeus Capital joins DirectorsTalk Interviews. Mike explains who Staffline Group are, what makes them..

LSL Property Services has considerable value and strategically positioned (Analyst Interview)

LSL Property Services plc (LON:LSL) is the topic of conversation when Robin Savage, Research Analyst at Zeus Capital joins DirectorsTalk Interviews. Robin talks us through the key points in the..

Safestyle UK should outperform peers in the sector (Analyst Interview)

Safestyle UK plc (LON:SFE) is the topic of conversation when Andy Hanson, Research Director at Zeus Capital joins DirectorsTalk Interviews. Andy explains how Safestyle UK traded during the year, the..

Goodbody Health a pivotal moment in community pharmacy (Interview)

Goodbody Health Inc. (CSE:GDBY / AQSE:GDBY / FRA: 484 / OTC: SCNNF) Scientific Advisory Committee Member and Chair of the Pharmacy Focus Group Ian Strachan joins DirectorsTalk Interviews to tell..

N4 Pharma encouraging data, oncology the quickest route to clinic (Interview)

N4 Pharma plc (LON:N4P) CEO Nigel Theobald joins DirectorsTalk to discuss encouraging data from its oncology research. Nigel describes the behavior of Nuvec, explains why now a focus on oncology,..

Search

Funds

Interviews

Search

Funds

Interviews

FTSE 100

Funds